<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7076519/results/search/disease/results.xml">
  <result pre="of natural shelled (NPRE) pistachios kernels (Pistacia vera L.) on" exact="herpes" post="simplex virus type 1 (HSV-1) replication. The Vero cell"/>
  <result pre="(NPRE) pistachios kernels (Pistacia vera L.) on herpes simplex virus" exact="type 1" post="(HSV-1) replication. The Vero cell line was used to"/>
  <result pre="NPRE (0.4, 0.6, 0.8 mg/mL) reduced the expression of the" exact="viral" post="proteins ICP8 (infected cell polypeptide 8), UL42 (unique long"/>
  <result pre="(unique long UL42 DNA polymerase processivity factor), and US11 (unique" exact="short" post="US11 protein), and resulted in a decrease of viral"/>
  <result pre="(unique short US11 protein), and resulted in a decrease of" exact="viral" post="DNA synthesis. The 50% cytotoxic concentration (CC50), 50% inhibitory"/>
  <result pre="natural shelled pistachio kernels have remarkable inhibitory activity against HSV-1." exact="herpes" post="simplex virus antiviral pistachios polyphenols 1. Introduction Herpes simplex"/>
  <result pre="virus antiviral pistachios polyphenols 1. Introduction Herpes simplex virus (HSV)" exact="infection" post="is quite common in adults and neonates and is"/>
  <result pre="with oral mucocutaneous lesions and/or genital infections. HSV-1 is the" exact="primary" post="cause of neonatal and sporadic encephalitis and, in absence"/>
  <result pre="lesions and/or genital infections. HSV-1 is the primary cause of" exact="neonatal" post="and sporadic encephalitis and, in absence of treatment, the"/>
  <result pre="infections. HSV-1 is the primary cause of neonatal and sporadic" exact="encephalitis" post="and, in absence of treatment, the mortality rate associated"/>
  <result pre="the primary cause of neonatal and sporadic encephalitis and, in" exact="absence of" post="treatment, the mortality rate associated with central HSV infection"/>
  <result pre="absence of treatment, the mortality rate associated with central HSV" exact="infection" post="is around 70% [1]. Furthermore, the virus persists in"/>
  <result pre="are widely used for the prophylaxis and treatment of HSV" exact="infections" post="[2]. These drugs are considered first-line drug treatments for"/>
  <result pre="[2]. These drugs are considered first-line drug treatments for HSV" exact="infections" post="and they have a similar anti-HSV mechanism. However, more"/>
  <result pre="similar anti-HSV mechanism. However, more than 40% of humans have" exact="recurrent" post="infections, and repeated pharmacological treatment often results in the"/>
  <result pre="triphosphate for the HSV-encoded DNA polymerase enzyme, thus blocking the" exact="viral" post="replication. The mechanism of drug-resistance is due to several"/>
  <result pre="[17,18], showing that polyphenols from pistachios have bactericidal activity against" exact="Listeria" post="monocytogenes, Staphylococcus aureus, and MRSA (methicillin-resistant Staphylococcus aureus) strains."/>
  <result pre="Thus, both NPRE and NP MIX were tested against HSV" exact="type I" post="by binding assay. The data of the antiviral effect"/>
  <result pre="were the most abundant compounds, followed by caffeic acid. The" exact="total" post="amount of polyphenols was 8.1 mg/100 g fresh weight"/>
  <result pre="different concentrations of NPRE for 24 h and the cell" exact="morphology" post="was then observed. The preliminary screening indicated that treatment"/>
  <result pre="Reduction Assay The antiviral effect of NPRE was determined against" exact="herpes" post="simplex virus type 1 (HSV-1) by using (i) plaque"/>
  <result pre="antiviral effect of NPRE was determined against herpes simplex virus" exact="type 1" post="(HSV-1) by using (i) plaque reduction assay, (ii) analysis"/>
  <result pre="(HSV-1) by using (i) plaque reduction assay, (ii) analysis of" exact="viral" post="protein expression, and (iii) quantification of viral DNA. For"/>
  <result pre="(ii) analysis of viral protein expression, and (iii) quantification of" exact="viral" post="DNA. For plaque reduction assay, HSV-1 was serially diluted"/>
  <result pre="50 PFU (plaque forming unit) in 100 µL, and the" exact="viral" post="suspension was added on Vero cells and incubated for"/>
  <result pre="polyphenol compounds were used (data not shown). 2.4. Analysis of" exact="Viral" post="Protein Expression The results from the plaque reduction assay"/>
  <result pre="compounds were used (data not shown). 2.4. Analysis of Viral" exact="Protein" post="Expression The results from the plaque reduction assay showed"/>
  <result pre="in the control samples. The samples were lysed and the" exact="total" post="cellular proteins were separated by SDS-PAGE. The optical densitometry"/>
  <result pre="UL42 DNA polymerase processivity factor (UL42) β proteins, necessary for" exact="viral" post="DNA replication, and the unique short US11 (US11) tegument"/>
  <result pre="β proteins, necessary for viral DNA replication, and the unique" exact="short" post="US11 (US11) tegument γ protein. As shown in Figure"/>
  <result pre="2), infected and treated cells accumulated a small amount of" exact="viral" post="ICP8, UL42, and US11 proteins (lane 3, lane 4,"/>
  <result pre="maximal non-cytotoxic concentration (0.8 mg/mL; lane 5). 2.5. Quantification of" exact="Viral" post="DNA In order to investigate whether the decrease on"/>
  <result pre="on the aforementioned protein level resulted in a decrease of" exact="viral" post="DNA synthesis, we performed a quantitative real-time PCR analysis"/>
  <result pre="were uninfected (mock) or infected with HSV-1 at multiplicity of" exact="infection" post="(MOI) 1 and treated or untreated with 0.6 and"/>
  <result pre="PCR analysis. As shown in Figure 4, the accumulation of" exact="viral" post="DNA was significantly reduced in the infected and treated"/>
  <result pre="synthesis process, and this resulted in a final decrease of" exact="viral" post="DNA synthesis. 2.6. Binding Assay Using NPRE and NP"/>
  <result pre="of action of polyphenols in the process of inhibition of" exact="viral" post="replication. The previous data showed that treatment with 0.8"/>
  <result pre="a 100% reduction in the number of plaques and reduced" exact="viral" post="DNA and protein accumulation, compared to the control. Furthermore,"/>
  <result pre="useful test to verify whether the binding phase of the" exact="infectious" post="process is inhibited by the treatment. The assay was"/>
  <result pre="named as HSV-1-VP26 GFP expressing a GFP (green fluorescent protein)-tagged" exact="viral" post="protein 26 (VP26) and by measuring the auto-fluorescence of"/>
  <result pre="(VP26) and by measuring the auto-fluorescence of VP26-tagged protein. The" exact="viral" post="suspension was incubated for 1 h at 4 °C"/>
  <result pre="h at 4 °C with the NPRE (0.8 mg/mL). The" exact="infection" post="was conducted at 4 °C, allowing the virus to"/>
  <result pre="the polyphenol-rich extracts of natural shelled pistachios. The inhibition of" exact="viral" post="replication was evaluated by binding assay using VP26-HSV-1 virus."/>
  <result pre="MIX resulted in a 50% decrease of the auto-fluorescence of" exact="viral" post="protein VP26 (Figure 5a,b) as well as a decreased"/>
  <result pre="recombination between HSV-1 and HSV-2 in humans, resulting in increasing" exact="genital herpes" post="due to HSV-1 [21,22]. Therefore, herpes viruses have become"/>
  <result pre="between HSV-1 and HSV-2 in humans, resulting in increasing genital" exact="herpes" post="due to HSV-1 [21,22]. Therefore, herpes viruses have become"/>
  <result pre="resulting in increasing genital herpes due to HSV-1 [21,22]. Therefore," exact="herpes" post="viruses have become a potential risk factor for HIV"/>
  <result pre="Therefore, herpes viruses have become a potential risk factor for" exact="HIV infection" post="in humans, and there is an increased need to"/>
  <result pre="herpes viruses have become a potential risk factor for HIV" exact="infection" post="in humans, and there is an increased need to"/>
  <result pre="esteroide, glycoside, and tannin have been found to interfere with" exact="viral" post="replication [8,23,24,25]. In particular, extracts rich in polyphenols have"/>
  <result pre="rich in polyphenols have been found to interfere with the" exact="viral" post="particles directly through inhibition of virus attachment [26]. In"/>
  <result pre="step, suggesting that NPRE might interfere with the expression of" exact="viral" post="proteins by preventing their transcription or translation, and this"/>
  <result pre="or translation, and this resulted in a final decrease of" exact="viral" post="DNA as well. To note, the pre-treatment of the"/>
  <result pre="to a significant reduction of the expression of VP26 GFP" exact="viral" post="protein, resulting in a decreased infectivity of the virus."/>
  <result pre="therapeutic effect of a polyphenols mix from NPRE. Given their" exact="lower" post="cellular tolerability (data not shown), further investigation should be"/>
  <result pre="analyses showed that polyphenols from pistachios are bioaccessible in the" exact="upper" post="gastrointestinal tract [27]. However, it seems that compounds not"/>
  <result pre="and Methods 4.1. Plant Material, Extraction, and NP MIX Preparation" exact="American" post="natural shelled (NP) pistachio kernels were kindly provided by"/>
  <result pre="gallic acid, protocatechuic acid, caffeic acid, rutin, and isoquercetin) were" exact="acquired" post="from Extrasynthese (Genay, France) and mixed in the same"/>
  <result pre="the NP extract (30:20:15:15:11:5:4, w/w). 4.2. Cell Culture and Virus" exact="African" post="green monkey kidney cell line (Vero) was cultured in"/>
  <result pre="from Vero cells infected with HSV-1 at low multiplicity of" exact="infection" post="(MOI) and harvested at 24 h post infection (p.i.)."/>
  <result pre="multiplicity of infection (MOI) and harvested at 24 h post" exact="infection" post="(p.i.). The cell-free supernatant containing the viral suspension was"/>
  <result pre="24 h post infection (p.i.). The cell-free supernatant containing the" exact="viral" post="suspension was stored at −80 °C and used for"/>
  <result pre="the experiments. Vero cell lines were originally obtained from the" exact="American" post="Type Culture Collection (ATCC). 4.3. Cell Viability to Test"/>
  <result pre="incubated with 50 PFU (plaque forming unit) of HSV-1. The" exact="viral" post="suspension was adsorbed on cells for 1 h at"/>
  <result pre="counted by crystal violet staining at 10× magnification with an" exact="inverted" post="microscope (Leica DMIL). 4.5. Binding Assay to Test the"/>
  <result pre="but not the entry as previously reported [26]. Briefly, the" exact="viral" post="suspension was incubated with the NPRE (0.8 mg/mL) and"/>
  <result pre="were then infected with the virus inoculum at multiplicity of" exact="infection" post="(MOI) of 1, and the infection was performed at"/>
  <result pre="inoculum at multiplicity of infection (MOI) of 1, and the" exact="infection" post="was performed at 4 °C with gentle shaking for"/>
  <result pre="and fresh media was then added. After 24 h post" exact="infection" post="(p.i.), the expression of the VP26 GFP protein was"/>
  <result pre="UL42, and γ protein US11. Specific proteins were detected using" exact="secondary" post="anti-mouse antibody linked to horseradish peroxidase (HRP). The chemiluminescence"/>
  <result pre="II System (Cepheid Europe, Maurens-Scopont, France), using specific TaqMan probe." exact="Total" post="cellular DNA (1 µg) was mixed with 0.5 μM"/>
  <result pre="U/µL of thermostable DNA polymerase BIOTAQ (BIO-21040 Bioline) in a" exact="total" post="volume of 25 µL. The oligonucleotide primer pairs were"/>
  <result pre="of the manuscript. Funding This research was funded by the" exact="American" post="Pistachio Growers (Fresno, CA, USA) and by a grant"/>
  <result pre="declare no conflict of interest. References References 1.TylerK.L.Herpes simplex virus" exact="infections" post="of the central nervous system: Encephalitis and meningitis, including"/>
  <result pre="References 1.TylerK.L.Herpes simplex virus infections of the central nervous system:" exact="Encephalitis" post="and meningitis, including Mollaret’sHerpes200411Suppl. 257A64A15319091 2.WhitleyR.New approaches to the"/>
  <result pre="2.WhitleyR.New approaches to the therapy of HSV infectionsHerpes200613535516895657 3.PiretJ.BoivinG.Resistance of" exact="herpes" post="simplex viruses to nucleoside analogues: Mechanisms, prevalence, and managementAntimicrob."/>
  <result pre="prevalence, and managementAntimicrob. Agents Chemother.20115545947210.1128/AAC.00615-1021078929 4.ChakrabartiS.PillayD.RatcliffeD.CaneP.A.CllinghanK.E.MilliganD.W.Resistance to antiviral drugs in" exact="herpes" post="simplex virus infections among allogenic stem cell transplant recipients:"/>
  <result pre="Agents Chemother.20115545947210.1128/AAC.00615-1021078929 4.ChakrabartiS.PillayD.RatcliffeD.CaneP.A.CllinghanK.E.MilliganD.W.Resistance to antiviral drugs in herpes simplex virus" exact="infections" post="among allogenic stem cell transplant recipients: Risk factors and"/>
  <result pre="recipients: Risk factors and prognostic significanceJ. Infect. Dis.20001812055205810.1086/31552410837192 5.ChenY.ScieuxV.GarraitV.SocieG.RochaV.MolinaJ.M.ThouvenotD.MorfinF.HocquelouxI.GardereiL.et al.Resistant" exact="herpes" post="simplex virus type 1 infection: An emerging concern after"/>
  <result pre="and prognostic significanceJ. Infect. Dis.20001812055205810.1086/31552410837192 5.ChenY.ScieuxV.GarraitV.SocieG.RochaV.MolinaJ.M.ThouvenotD.MorfinF.HocquelouxI.GardereiL.et al.Resistant herpes simplex virus" exact="type 1" post="infection: An emerging concern after allogenetic stem cell transplantationClin."/>
  <result pre="concern after allogenetic stem cell transplantationClin. Infect. Dis.20003192793510.1086/31405211049772 6.LevinM.J.BaconT.H.LearyJ.J.Resistance of" exact="herpes" post="simplex virus infections to nucleoside analogues in HIV-infected patientsClin."/>
  <result pre="stem cell transplantationClin. Infect. Dis.20003192793510.1086/31405211049772 6.LevinM.J.BaconT.H.LearyJ.J.Resistance of herpes simplex virus" exact="infections" post="to nucleoside analogues in HIV-infected patientsClin. Infect Dis.200439Suppl. 5S248S25710.1086/42236415494896"/>
  <result pre="glycosides and phenolic compounds of Plantago speciesPlanta Med.20036960060410.1055/s-2003-4111312898413 10.KutluayS.B.DoroghaziJ.RoemerM.E.TriezenbergS.J.Curcumin inhibits" exact="herpes" post="simplex virus immediate-early gene expression by a mechanism independent"/>
  <result pre="HSV-1 in Vero cell lineNat. Prod. Commun.201051935193810.1177/1934578X100050122021299124 12.de OliveiraA.AdamsS.D.LeeL.H.MurrayS.R.HsuS.D.HammondJ.R.DickinsonD.ChenP.ChuT.C.Inhibition of" exact="herpes" post="simplex virus type 1 with the modified green tea"/>
  <result pre="cell lineNat. Prod. Commun.201051935193810.1177/1934578X100050122021299124 12.de OliveiraA.AdamsS.D.LeeL.H.MurrayS.R.HsuS.D.HammondJ.R.DickinsonD.ChenP.ChuT.C.Inhibition of herpes simplex virus" exact="type 1" post="with the modified green tea polyphenol palmitoyl-epigallocatechin gallateFood Chem."/>
  <result pre="leavesFitoterapia20128336236710.1016/j.fitote.2011.11.01422155188 14.HsiangC.Y.HoT.Y.Emodin is a novel alkaline nuclease inhibitor that suppresses" exact="herpes" post="simplex virus type 1 yields in cell culturesBr. J."/>
  <result pre="a novel alkaline nuclease inhibitor that suppresses herpes simplex virus" exact="type 1" post="yields in cell culturesBr. J. Pharmacol.200815522723510.1038/bjp.2008.24218552872 15.XiongH.R.LuoJ.HouW.XiaoH.YangZ.Q.The effect of"/>
  <result pre="anthraquinone derivative extracted from the roots of Rheum tanguticum, against" exact="herpes" post="simplex virus in vitro and in vivoJ. Ethnopharmacol.201113371872310.1016/j.jep.2010.10.05921050882 16.RezazadehF.MoshaveriniaM.MotamedifarM.AlyaseriM.Assessment"/>
  <result pre="Circulating Human Herpes Simplex VirusesJ. Infect. Dis.2019jiz19910.1093/infdis/jiz19931016321 22.RobertsC.M.PfisterJ.R.SpearS.J.Increasing proportion of" exact="herpes" post="simplex virus type 1 as a cause of genital"/>
  <result pre="Simplex VirusesJ. Infect. Dis.2019jiz19910.1093/infdis/jiz19931016321 22.RobertsC.M.PfisterJ.R.SpearS.J.Increasing proportion of herpes simplex virus" exact="type 1" post="as a cause of genital herpes infection in college"/>
  <result pre="of herpes simplex virus type 1 as a cause of" exact="genital herpes" post="infection in college studentsSex Transm. Dis.20033079780010.1097/01.OLQ.0000092387.58746.C714520181 23.KhanM.T.H.AtherA.ThompsonK.D.GambariR.Extracts and molecules"/>
  <result pre="herpes simplex virus type 1 as a cause of genital" exact="herpes" post="infection in college studentsSex Transm. Dis.20033079780010.1097/01.OLQ.0000092387.58746.C714520181 23.KhanM.T.H.AtherA.ThompsonK.D.GambariR.Extracts and molecules"/>
  <result pre="simplex virus type 1 as a cause of genital herpes" exact="infection" post="in college studentsSex Transm. Dis.20033079780010.1097/01.OLQ.0000092387.58746.C714520181 23.KhanM.T.H.AtherA.ThompsonK.D.GambariR.Extracts and molecules from"/>
  <result pre="studentsSex Transm. Dis.20033079780010.1097/01.OLQ.0000092387.58746.C714520181 23.KhanM.T.H.AtherA.ThompsonK.D.GambariR.Extracts and molecules from medicinal plants against" exact="herpes" post="simplex virusesAntivir. Res.20056710711910.1016/j.antiviral.2005.05.00216040137 24.HassanS.T.MasarčíkováR.BerchováK.Bioactive natural products with anti-herpes simplex"/>
  <result pre="(SD) of three experiments. Figure 2 Effects of NPRE on" exact="herpes" post="simplex 1 (HSV-1) replication by plaque reduction assay. Vero"/>
  <result pre="less than 0.01 and 0.001, respectively. Figure 3 Analysis of" exact="viral" post="protein expression by Western blot analysis. Figure 4 Relative"/>
  <result pre="expression by Western blot analysis. Figure 4 Relative quantization of" exact="viral" post="DNA with specific HSV-1 TaqMan probe in real-time PCR."/>
  <result pre="GFP (green fluorescent protein-tagged capsid protein VP26) at multiplicity of" exact="infection" post="(MOI) 1, as described in the Materials and Methods"/>
  <result pre="section. Then, the cells were analysed at 24 h post" exact="infection" post="(p.i.): (a) fluorescent images showed the green dots representing"/>
  <result pre="fluorescent images showed the green dots representing the VP26 GFP" exact="viral" post="antigen localization (I)—Hoechst (blue) was used to stain the"/>
 </snippets>
</snippetsTree>
